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Abstract
Population-adjusted indirect comparisons are used to estimate treatment effects
when there are cross-trial differences in effect modifiers and when access to individual
patient data is limited. Increasingly, health technology assessment agencies are ac-
cepting evaluations that use these methods across a diverse range of therapeutic areas.
Popular methods include matching-adjusted indirect comparison (MAIC) and simu-
lated treatment comparison (STC). Despite this increasing popularity, there is limited
formal evaluation of these methods and whether they can be used to accurately com-
pare treatments. Thus, we undertake a comprehensive simulation study to compare
standard unadjusted indirect comparisons, MAIC and STC across 162 scenarios. This
simulation study assumes that the trials are investigating survival outcomes and mea-
sure binary covariates, with the log hazard ratio as the measure of effect. This is
one of the most widely used setups in health technology assessment applications. The
simulation scenarios vary the trial sample size, prognostic variable effects, interaction
effects, covariate correlations and covariate overlap. Generally, MAIC yields unbiased
treatment effect estimates, while STC is often biased with non-linear link functions
and may overestimate variability. Standard indirect comparisons are systematically
biased, particularly under stronger covariate imbalance and interaction effects. Cover-
age rates are valid for MAIC. Interval estimates for the standard indirect comparison
are too narrow and STC suffers from overcoverage or from bias-induced undercover-
age. MAIC provides the most accurate estimates and, with lower degrees of covariate
overlap, its bias reduction outweighs the loss in effective sample size and precision.
Keywords: Health technology assessment; indirect treatment comparison; simu-
lation study; oncology; clinical trials; comparative effectiveness research
1 Introduction
Evaluating the comparative efficacy of alternative health care interventions lies at the heart
of health technology assessments (HTAs), such as those commissioned by the National In-
stitute of Health and Care Excellence (NICE), the body responsible for providing guidance
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on whether health care technologies should be publicly funded in England and Wales [1].
The randomized controlled trial (RCT) is the most reliable design for estimating the rela-
tive effectiveness of new treatments [2]. However, new treatments are typically compared
against placebo or standard of care before the licensing stage, but not necessarily against
other active interventions — a comparison that is required for HTAs. In the absence of
data from head-to-head RCTs, indirect treatment comparisons (ITCs) are at the top of
the hierarchy of evidence when assessing the relative effectiveness of interventions and can
inform treatment and reimbursement decisions [3].
Standard ITC techniques, such as network meta-analysis, are useful when there is a
common comparator arm between RCTs, or more generally a connected network of studies
[3, 4]. These methods can be used with individual patient data (IPD) or aggregate-level
data (ALD), with IPD considered the gold standard [5]. However, standard ITCs assume
that there are no cross-trial differences in the distribution of effect-modifying variables
(constant relative effects) and produce biased estimates when these exist [6]. Popular
balancing methods such as propensity score matching [7] can account for these differences
but require access to IPD for all the studies being compared [8].
In many HTA processes, there are: (1) no head-to-head trials comparing the inter-
ventions of interest; (2) IPD available for at least one intervention (e.g. from the sub-
mitting company’s own trial), but only published ALD for the relevant comparator(s);
and (3) cross-trial differences in effect-modifying baseline characteristics, implying that
the relative effects are not constant. Several methods, labeled population-adjusted indirect
comparisons, have been introduced to estimate relative treatment effects in this scenario.
These include matching-adjusted indirect comparison (MAIC) [9, 10, 11] and simulated
treatment comparison (STC) [12] and generally require access to IPD from at least one of
the trials.
The NICE Decision Support Unit has published formal submission guidelines for pop-
ulation adjustment with limited access to IPD [6, 13]. Various reviews [6, 13, 14, 15]
define the relevant terminology and assess the theoretical validity of these methodologies
but do not express a preference. Questions remain about the correct application of the
methods and their validity in HTA [6, 16, 13]. Thus, Phillippo et al. [6] state that current
guidance can only be provisional, as more thorough understanding of the properties of
population-adjusted indirect comparisons is required.
Consequently, several simulation studies have been published since the release of the
NICE guidance [17, 18, 19, 20, 21, 22]. These have primarily assessed the performance of
MAIC relative to standard ITCs in a limited number of simulation scenarios. In general,
the studies set relatively low effect modifier imbalances and do not vary these, even though
MAIC may lead to large reductions in effective sample size and imprecise estimates of the
treatment effect when imbalances are high [23].
In this paper, we carry out a comprehensive simulation study to benchmark the perfor-
mance of MAIC and STC against the standard ITC. The simulation study evaluates these
methods in a wide range of settings; varying the trial sample size, effect-modifying strength
of covariates, explanatory power of covariates, covariate imbalance and correlation levels.
A total of 162 simulation scenarios are considered, providing the most extensive evaluation
of population adjustment methods to date. A complementary objective of the simulation
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study is to inform the circumstances under which population adjustment should be applied
and which specific method is preferable in a given situation.
In Section 2, we establish the context and data requirements for population-adjusted
indirect comparisons. In Section 3, MAIC and STC are presented. Section 4 describes a
simulation study, which extensively evaluates the properties of these approaches under a
variety of conditions. Section 5 presents results from the simulation study. An extended
discussion of our findings and their implications is provided in Section 6. Finally, we make
some concluding remarks in Section 7.
2 Context
HTA typically takes place late in the drug development process, after a new medical
technology has obtained regulatory approval, typically based on a two-arm RCT that
compares the new intervention to the placebo or standard or care. In this case, the
question of interest is whether or not the drug is effective. In HTA, the relevant policy
question is: “given that there are finite resources available to finance or reimburse health
care, which is the best treatment of all available options in the market?”. In order to
answer this question, one must evaluate the relative efficacy of interventions that may not
have been trialed against each other.
Indirect treatment comparison methods are used when we wish to compare the relative
effect of interventions A and B for a specific outcome, but no head-to-head trials are
currently available. Typically, it is assumed that the comparison is undertaken using
additive effects for a given linear predictor, e.g. log hazard ratio for time-to-event outcomes
or log-odds ratio for binary outcomes. Indirect comparisons are typically performed on this
scale [3, 4]. In addition, we assume that the comparison is “anchored”, i.e., a connected
treatment network is available through a common comparator C, e.g. placebo or standard
of care. We note that comparisons can be unanchored, e.g. using single-arm trials or
disconnected treatment networks, but this requires much stronger assumptions [6]. The
NICE Decision Support Unit discourages the use of unanchored comparisons when there
is connected evidence and labels these as problematic [6, 13]. Hence, we do not present
the methodology behind these.
A manufacturer submitting evidence for reimbursement to HTA bodies has access
to patient-level data from its own trial that compares its product A against standard
intervention C. However, as disclosure of proprietary, confidential patient-level data from
industry-sponsored clinical trials is rare, IPD for the competitor’s trial, comparing its
treatment B against C, are, almost invariably, unavailable. We consider, without loss of
generality, that IPD are available for a trial comparing intervention A to intervention C
(denoted AC) and published ALD are available for a trial comparing B to C (BC).
Standard methods for indirect comparisons such as the Bucher method [4], a spe-
cial case of network meta-analysis, allow for the use of ALD and estimate the A vs. B
treatment effect as ∆ˆAB = ∆ˆAC − ∆ˆBC , where ∆ˆAC is the relative treatment effect of A
vs. C (observed in the AC population), and ∆ˆBC is the relative effect of B vs. C (in the
BC population). The treatment effect ∆ˆAC and its variance can be estimated from the
available IPD. The treatment effect ∆ˆBC and its variance may be directly published or
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derived from aggregate outcomes made available in the literature. As the indirect com-
parison is based on relative treatment effects observed in separate RCTs, the within-trial
randomization of the originally assigned patient groups is preserved. The within-trial rel-
ative effects are statistically independent of each other; hence, their variances are simply
summed (or derived empirically from a Bayesian analysis) to obtain the variance of the A
vs. B treatment effect.
Standard indirect comparisons assume that there are no cross-trial differences in the
distribution of effect-modifying variables. That is, the relative treatment effect of A vs. C
in the AC population (indicated as ∆AC) is assumed equivalent to the treatment effect that
would occur in the BC population (denoted ∆∗AC) — throughout the paper the asterisk
superscript indicates that the variable of interest, in this case the relative treatment effect
observed in one population (AC), has been “mapped” into the effect that would have been
observed in a different population, in this case BC.
Often, treatment effects are influenced by variables that interact with treatment on
a specific scale (e.g. the linear predictor), altering the effect of treatment on outcomes.
If these effect modifiers are distributed differently across AC and BC, relative treatment
effects differ in the trial populations and the assumptions of the Bucher method are broken.
In this case, a standard ITC between A and B is liable to bias and may produce overly
precise efficacy estimates [24]. From the economic modelling point of view, these features
are undesirable, as they impact negatively on the “probabilistic sensitivity analysis” [25],
the (often mandatory) process used to characterise the impact of the uncertainty in the
model inputs on the decision-making process.
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Figure 1: Number of peer-reviewed publications and technology appraisals from the Na-
tional Institute for Health and Care Excellence (NICE) using population-adjusted indirect
comparisons per year.
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The use of population adjustment in HTA, both in published literature as well as in sub-
missions for reimbursement, and its acceptability by national HTA bodies, e.g. in England
and Wales, Scotland, Canada and Australia [16], is increasing across diverse therapeutic
areas [16, 26, 23, 27]. As of April 11, 2020, a search among titles, abstracts and keywords
for “matching-adjusted indirect comparison” and “simulated treatment comparison” in
Scopus, reveals at least 89 peer-reviewed applications of MAIC and STC and conceptual
papers about the methods. In addition, at least 30 technology appraisals (TAs) published
by NICE use MAIC or STC — of these, 23 have been published since 2017. Figure 1
shows the rapid growth of peer-reviewed publications and NICE TAs featuring MAIC or
STC since the introduction of these methods in 2010. MAIC and STC are predominantly
applied in the evaluation of cancer drugs, as 26 of the 30 NICE TAs using population
adjustment have been in oncology.
3 Methodology
We shall assume that the following data are available for the i−th subject (i = 1, . . . , N)
in the AC trial, of size N :
• A vector of K baseline characteristics Xi = (Xi,1, . . . , Xi,K), e.g. age, gender, co-
morbidities;
• A treatment indicator Ti. Without loss of generality, we assume here for simplicity
that Ti ∈ {0, 1} for the common comparator and active treatment, respectively;
• An observed outcome Yi, e.g. a time-to-event or binary indicator for some clinical
measurement.
Given this information, we can estimate the A vs. C treatment effect in the AC population,
which we indicate as ∆ˆAC , and derive its variance.
For the BC trial, data available are:
• Published summary values θ, e.g. proportions or means and standard deviations
for the baseline characteristics. We shall assume that these are available for K
covariates.
• Estimates of the B vs. C treatment effect in the BC population, ∆ˆBC , and its
variance, either published directly or derived from aggregate outcomes from the
literature.
The baseline characteristics can be classed as prognostic variables (covariates that af-
fect outcome), effect modifiers (covariates that interact with treatment to affect outcome),
both or none. For simplicity in the notation, it is assumed that all available baseline char-
acteristics are prognostic of the outcome and that a subset of these, X
(EM)
i ⊂ Xi, are
selected as effect modifiers on the linear predictor scale. Similarly, for the published sum-
mary values, θ(EM) ⊂ θ. Appendix A of the Supplementary Material provides an in-depth
discussion of the assumptions made by population adjustment methods.
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3.1 Matching-adjusted indirect comparison
Matching-adjusted indirect comparison (MAIC) is a population adjustment method based
on inverse propensity score weighting [28]. IPD from the AC trial are weighted so that
the means of specified covariates match those in the BC trial. The mean outcomes under
treatment t ∈ {0, 1} (for C and A, respectively) in the BC population are predicted as
the weighted average:
Yˆ ∗t =
∑Nt
i=1 Yi,twi∑Nt
i=1wi
,
where Yi,t denotes the outcome for patient i receiving treatment t in the patient-level
data and Nt represents the number of patients in arm t of the AC trial. Each individual
is assigned a weight wi, which represents the odds of being enrolled in the BC trial
as opposed to being enrolled in the AC trial and is defined as a function of the effect-
modifying baseline characteristicsX
(EM)
i . Note that we have summary data from the BC
trial to estimate absolute outcomes under C. However, in this instance, we wish to use the
predicted outcomes Yˆ ∗t=0 to generate a relative effect for A vs. C in the BC population.
Typically, the weights are estimated using a propensity score logistic regression model
such that log (wi) = α0 +X
(EM)
i α1. However, the regression parameters cannot be de-
rived using conventional methods (e.g. maximum-likelihood), because IPD are not avail-
able for BC. Signorovitch et al. [9] propose using a method of moments to estimate the
model parameters by setting the weights so that the mean covariates are exactly balanced
across the two trial populations. One can also balance higher order terms, e.g. by in-
cluding squared covariates in the method of moments to match variances. However, this
decreases the degrees of freedom and may increase finite sample bias [29]. Matching both
means and variances (as opposed to means only) appears to result in more biased and less
accurate treatment effect estimates when covariate variances differ across trials [18, 20].
In the original MAIC approach, covariates are matched for active treatment and control
arms combined and standard errors are computed using a robust sandwich estimator
[9, 30]. This estimator does not rely upon strong assumptions about the MAIC weights.
It is empirically derived from the data and accounts for the uncertainty in the estimation of
the weights rather than assuming that these are fixed and known. Proposed modifications
to MAIC are based on entropy balancing [18, 21], performing the matching separately for
active and control arms [18, 21], and using the bootstrap [31, 32] to compute standard
errors [33].
As MAIC is a reweighting procedure, it will reduce the effective sample size (ESS) of
the AC trial. The approximate ESS of the trial is estimated as (
∑
i wˆi)
2 /
∑
i wˆ
2
i , where wˆi
is the weight estimated for individual i using the method of moments. For relative effects
to be conditionally constant and eventually produce an unbiased indirect comparison, one
needs to include all effect modifiers in the weighting procedure. However, including too
many covariates or large covariate imbalance (poor overlap in the covariate distributions)
can lead to extreme weights and give treatment effect estimates with poor precision [34].
In general, this is a pervasive problem in NICE TAs as most of the reported ESSs are
small with a large percentage reduction from the original sample size [23].
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3.2 Simulated treatment comparison
While MAIC is a reweighting method, simulated treatment comparison (STC) is based on
regression adjustment [35]. IPD from the AC trial are used to fit a regression model be-
tween the outcome and the baseline characteristics. In STC, the following linear predictor
is fitted to the IPD:
g(η∗i ) = β0 + (Xi − µ)β1 +
[
βT +
(
X
(EM)
i − µ(EM)
)
β2
]
1(Ti = 1), (1)
where η∗i is the expected outcome (in theBC population) of subject i, g(·) is an appropriate
link function (e.g. logit for binary outcomes), β0 is the intercept, β1 is a vector of K
regression coefficients for the prognostic variables, β2 is a vector of interaction coefficients
for the effect modifiers and βT is the A vs. C treatment coefficient. The prognostic
variables and effect modifiers are centered at the published mean values from the BC
population, µ and µ(EM), respectively. Hence, the estimated βˆT is directly interpreted
as the A vs. C treatment effect in the BC population.
Similarly to MAIC, for relative effects to be conditionally constant, one needs to include
all effect modifiers in the model. However, it is optional to include (and to center) variables
that are purely prognostic. As with any regression adjustment method, STC requires a
strong fit of the outcome model. NICE guidance [13] suggests adding purely prognostic
variables if they increase the precision of the model and account for more of its underlying
variance, as reported by model selection criteria (e.g. residual deviance or information
criteria). However, such tools should not guide decisions on effect modifier status, which
must be defined prior to fitting the outcome model. As effect-modifying covariates are
likely to be good predictors of outcome, the inclusion of appropriate effect modifiers should
provide an acceptable fit.
A major issue with the implementation of STC presented above is that it is systemat-
ically biased in the case of non-linear outcomes [14], e.g. binary outcomes modelled using
logistic regression or time-to-event outcomes. In linear models, the arithmetic mean of
the predicted outcome (the expected outcome for patients sampled under the centered
covariates) coincides with its geometric mean (the outcome evaluated at the expectation
of the centered covariates). However, this is not the case for models that are non-linear.
Initially, this hindered the widespread adoption of STC as most applications of population
adjustment in HTA are in oncology and are typically concerned with survival outcomes,
or rate outcomes such as response rates.
To address non-linearity bias, Ishak et al. [14, 36] propose simulating individualized
profiles based on the summary values of the BC covariates and the covariance matrix
observed in the AC trial. Ideally, the BC population should be characterized by the
full joint distribution of covariates. However, the restriction of limited IPD makes it
unlikely that the joint distribution of the BC covariates is available. Such distribution
must be approximated to avoid bias arising from the incomplete specification of the BC
population. Ishak et al. do so by simulating continuous covariates at the individual level
from a multivariate normal distribution with the BC means and AC correlation structure.
In this simulation-based approach, a regression of the outcome on the covariates is
fitted to the AC IPD. This regression is similar to that in Equation 1, although now the
7
prognostic variables and effect modifiers are not centered at the mean BC covariates,
g(ηi) = β0 +Xiβ1 + (βT +X
(EM)
i β2)1(Ti = 1), (2)
ηi is the (unadjusted) expected outcome of subject i and βT represents the baseline A
vs. C treatment effect (when the values of the prognostic variables and effect modifiers
are zero). The coefficients of this regression are applied to the covariates X∗s simulated
for each patient s, including the effect modifiers X
∗(EM)
s , to produce individual linear
predictors (e.g. the predicted log hazard or log-odds) in the BC population:
g(η∗s) = βˆ0 +X
∗
s βˆ1 + (βˆT +X
∗(EM)
s βˆ2)1(Ts = 1),
where βˆ0, βˆ1, βˆ2 and βˆT are the regression parameters estimated in Equation 2. The
individual linear predictors under each treatment t ∈ {0, 1} (for C and A respectively)
and their variances are averaged such that the A vs. C treatment effect is estimated as
∆ˆ∗AC = E[g(η∗t=1)] − E[g(η∗t=0)], and a measure of the variance is provided by Vˆ (∆ˆ∗AC) =
E[SE((g(η∗t=1))2] + E[SE((g(η∗t=0))2], where SE(·) denotes the fitted standard error of the
linear prediction. See [37, 38, 39] for recent applications of this methodology.
4 Simulation Study
4.1 Aims
The objectives of the simulation study are to compare MAIC, STC and the Bucher method
across a wide range of scenarios that may be encountered in practice. For each estima-
tor, we assess the following properties [40]: (1) unbiasedness; (2) variance unbiasedness;
(3) randomization validity;1 and (4) precision and efficiency. The selected performance
measures evaluate these criteria specifically (see 4.5). The simulation study is reported
following the ADEMP (Aims, Data-generating mechanisms, Estimands, Methods, Per-
formance measures) structure [40]. All simulations and analyses were performed using R
software version 3.6.3 [41].2
4.2 Data-generating mechanisms
As most applications of MAIC and STC are in oncology, the most prevalent outcome types
are survival or time-to-event outcomes (e.g. overall or progression-free survival) [23]. Hence
we consider these using the log hazard ratio as the measure of effect.
1In a sufficiently large number of repetitions, (1−α)% confidence intervals based on normal distributions
should contain the true value (1− α)% of the time, for a nominal significance level α.
2The files required to run the simulations are available at http://github.com/remiroazocar/
population_adjustment_simstudy. Appendix B of the Supplementary Material presents a more detailed
description of the simulation study design and Appendix C lists the specific settings of each simulation
scenario.
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Following Bender et al. [42], we simulate Cox-Weibull survival times τi for subject i
for trials AC and BC according to the formula:
τi =
(
− logUi
λ exp[Xiβ1 + (βT +X
(EM)
i β2)1(Ti = 1)]
)1/ν
, (3)
where Ui is a uniformly distributed random variable, Ui ∼ (0, 1). We set the inverse scale of
the Weibull distribution to λ = 8.5 and the shape to ν = 1.3 as these parameters produce
a functional form and treatment effect reflecting frequently observed mortality trends in
metastatic cancer patients [20]. Four correlated or uncorrelated binary covariates Xi are
generated per subject, following Leisch et al. [43]. Two of these are purely prognostic
variables; the other two (X
(EM)
i ) are effect modifiers and prognostic variables.
We introduce random right censoring to simulate loss to follow-up within each trial.
Censoring times τc,i are generated from the exponential distribution τc,i ∼ Exp(λc), where
the rate parameter λc = 0.96 is selected to achieve a censoring rate of 35% under the active
treatment at baseline (with the values of the prognostic variables and effect modifiers set
to zero), considered moderate censoring [44]. We fix the value of λc before generating the
datasets, by simulating survival times for 1,000,000 subjects with Equation 3 and using the
R function optim (Brent’s method [45]) to minimize the difference between the observed
and targeted censoring proportion.
For the BC trial, the individual-level covariates and outcomes are aggregated to obtain
summaries. The treatment effect ∆ˆBC and its variance are estimated through a Cox
proportional hazards regression.
The simulation study examines five factors in a fully factorial arrangement with 3 ×
3 × 3 × 2 × 3 = 162 scenarios to explore the interaction between factors. The simulation
scenarios are defined by the values of the following parameters:
• The number of patients in the AC trial, N ∈ {300, 450, 600} under a 1:1 active
intervention vs. control allocation ratio. The sample sizes correspond to typical
values for a Phase III RCT [46].
• The strength of the association between the prognostic variables and the outcome,
β1,k ∈ {− log(0.67),− log(0.5),− log(0.33)} (moderate, strong and very strong prog-
nostic variable effect). These regression coefficients correspond to fixing the con-
ditional hazard ratios for the effect of each prognostic variable at 1.5, 2 and 3,
respectively.
• The strength of interaction of the effect modifiers, β2,k ∈ {− log(0.67),− log(0.5),
− log(0.33)} (moderate, strong and very strong interaction effect). These parameters
have a material impact on the A vs. B treatment effect, biasing the log hazard
ratio by magnitudes of 0.24, 0.42 and 0.67, respectively, when covariate overlap is
moderate (see below). Hence, population adjustment is warranted in order to remove
the induced bias.
• The level of correlation between covariates, cor(Xi,k, Xi,l) ∈ {0, 0.35}, k 6= l (no
correlation and moderate correlation).
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• The degree of covariate imbalance, µk ∈ {0.4, 0.35, 0.3}, with Xi,k ∼ Bernoulli(µk)
for the AC trial (while, for the BC trial, simultaneously varying µk ∈ {0.6, 0.65, 0.7},
respectively). This yields strong, moderate and poor covariate overlap, with cross-
trial differences in proportions of 0.2, 0.3 and 0.4, respectively.
Each active intervention has a very strong baseline treatment effect βT = log(0.25)
versus the common comparator. The number of subjects in the BC trial is 600, under
a 1:1 active treatment vs. control allocation ratio. The prognostic variables and effect
modifiers may represent comorbidities, which are associated with shorter survival and, in
the case of the effect modifiers, which interact with treatment to render it less effective.
4.3 Estimands
The estimand of interest is the true marginal A vs. B treatment effect. As the true relative
effect βT = log(0.25) is identical for both A vs. C and B vs. C, the true A vs. B treatment
effect ∆AB = 0. We generate and analyze 1,000 Monte Carlo replicates of trial data per
simulation scenario. Let ∆ˆ∗AB,j denote the estimator (the adjusted A vs. B treatment
effect, in the BC population) for the j-th Monte Carlo replicate and let E(∆ˆ∗AB) denote
its mean across the 1,000 simulations.
4.4 Methods
Each simulated dataset is analyzed using the following methods:
• Matching-adjusted indirect comparison, as originally proposed by Signorovitch et
al. [9], where covariates are matched for active treatment and control arms com-
bined and weights are estimated using the method of moments. A weighted Cox
proportional hazards model is fitted to the IPD using the R package survey [47],
with the weights specified as sampling weights of a survey design. Standard errors
for the A vs. C treatment effect are computed using a robust sandwich-type variance
estimator based on Taylor series linearization [47].
• Simulated treatment comparison: a Cox proportional hazards regression on survival
time is fitted to the IPD, including all effect modifiers and prognostic variables. BC
covariates are simulated from a multivariate Gaussian copula [48], using Bernoulli-
distributed marginals with BC means, and the pairwise correlations of the AC
IPD. We simulate covariates for 100,000 patients, a value assumed large enough to
minimize the variability in sampling from the aggregate values, and keep the same
allocation ratio of the original AC trial. The A vs. C treatment effect (in the BC
population) is derived from the log hazards predicted for the simulated patients.
The original “plug-in” approach to STC, where a regression is fitted with the IPD
covariates centered at the BC mean values, is evaluated in the Supplementary Ma-
terial. We choose to include all of the prognostic variables in the regression but only
center the effect modifiers.
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• The Bucher method [4] gives the standard indirect comparison. We know that this
will be biased as it does not adjust for the bias induced by the imbalance in effect
modifiers.
In all methods, the variances of each within-trial relative effect are summed to estimate
the variance of the A vs. B treatment effect, Vˆ (∆ˆ∗AB). Confidence intervals are constructed
using normal distributions: ∆ˆ∗AB ± 1.96
√
Vˆ (∆ˆ∗AB), assuming relatively large N .
4.5 Performance measures
The following criteria are considered jointly to assess the methods’ performances:
• To assess aim 1, we compute the bias in the estimated treatment effect
E(∆ˆ∗AB −∆AB) =
1
1000
1000∑
j=1
∆ˆ∗AB,j −∆AB.
As ∆AB = 0, the bias is equal to the average treatment effect across the simulations.
• To assess aim 2, we calculate the variability ratio of the treatment effect estimate,
defined [49] as the ratio of the average standard error and the observed standard
deviation (empirical standard error):
VR(∆ˆ∗AB) =
1
1000
∑1000
j=1
√
Vˆ (∆ˆ∗AB,j)
1
999
∑1000
j=1 (∆ˆ
∗
AB,j − E(∆ˆ∗AB))2
.
VR > (<)1 suggests that, on average, standard errors overestimate (or underesti-
mate) the variability of the treatment effect estimate.
• Aim 3 is assessed using the coverage of confidence intervals, estimated as the pro-
portion of times that the true treatment effect is enclosed in the (1−α)% confidence
interval of the estimated treatment effect, where α = 0.05 is the nominal signifi-
cance level.
• We use empirical standard error (ESE) to assess aim 4 as it measures the preci-
sion or long-run variability of the treatment effect estimate:
ESE(∆ˆ∗AB) =
√√√√ 1
999
1000∑
j=1
(∆ˆ∗AB,j − E(∆ˆ∗AB))2.
• The mean square error (MSE) of the estimated treatment effect
MSE(∆ˆ∗AB) = E
[
(∆ˆ∗AB −∆AB)2
]
=
1
1000
1000∑
j=1
(∆ˆ∗AB,j −∆AB)2,
provides a summary value of overall accuracy (efficiency), integrating elements both
bias (aim 1) and variability (aim 4).
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5 Results
The performance measures across all 162 simulation scenarios are illustrated in Figures 2
to 6 using nested loop plots [50], which arrange all scenarios into a lexicographical order,
looping through nested factors. In the nested sequence of loops, we consider first the
parameters with the largest perceived influence on the performance metric. Notice that
a different order is selected for bias than for the other performance measures. Monte
Carlo standard errors quantifying the simulation uncertainty of each performance metric
are reported in Appendix D of the Supplementary Material. Additional performance
measures are considered in Appendix E of the Supplementary Material.
5.1 Unbiasedness of treatment effect
Figure 2 shows the bias for the methods across all scenarios. In a review of missing data
methods, Schafer and Graham [51] consider bias to be troublesome if its absolute size is
greater than about one half of the estimate’s empirical standard error. Under this rule
of thumb, MAIC does not produce problematic biases in any of the simulation scenarios.
On the other hand, STC and the Bucher method generate problematic biases in 101
of 162 scenarios, and in all 162 scenarios, respectively. The application of this rule is
somewhat arbitrary as the empirical standard error is dependent on several factors such
as the number of simulations, also set to 1,000 by Schafer and Graham. Most importantly,
the impact of the biases will depend on the uncertainty in the estimated treatment effect
[51, 52]. We consider standardizing the biases [52] by computing these as a percentage of
the empirical standard error in order to assess their impact.
In the missing data literature, standardized biases of magnitude greater than 40% have
been observed to considerably affect the precision, coverage and error rates of estimates.
For MAIC, no standardized biases are above such threshold in either direction, the maxi-
mum absolute value being 14.7% in a simulation scenario with very strong prognostic and
interaction effects. For STC, the magnitude of the standardized biases is above the 40%
threshold in 54 of 162 scenarios. The biases in MAIC do not appear to have any practical
significance, as they do not degrade coverage and efficiency. MAIC is the least biased
method, followed by STC and the Bucher method.
For STC, we adopted a “covariate simulation” approach, proposed by Ishak et al. [14]
to avoid the non-linearity bias arising when the mean BC effect modifiers are substituted
in Equation 1. However, we find that simulating the covariates at the individual level leads
to biases that are virtually identical to those of the “plug-in” approach (see Appendix D
and Appendix E of the Supplementary Material). Both implementations display the same
degree of systematic bias arising from the non-linear link function in the Cox regression.
In some cases, e.g. under very strong prognostic variable effects and moderate effect-
modifying interactions, STC even has increased bias compared to the Bucher method.
In the scenarios considered in this simulation study, STC produces negative bias when
the interaction effects are moderate and positive bias when they are very strong. In
addition, biases vary more widely when prognostic effects are larger. When interaction
effects are weaker, stronger prognostic effects shift the bias negatively. It is worth noting
that conclusions arising from the interpretation of patterns in Figure 2 for STC may be
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by-products of the non-linearity bias and should be interpreted with caution.
As expected, the strength of interaction effects is an important driver of bias in the
Bucher method and the incurred bias increases with poorer covariate overlap. This is
because the more substantial the imbalance in effect modifiers and the greater their in-
teraction with treatment, the larger the bias of the unadjusted comparison. The impact
of these factors on the bias appears to be slightly reduced when prognostic effects are
stronger and contribute more “explanatory power” to the outcome. Varying the number
of patients in the AC trial does not seem to have any discernible impact on the bias for
any method. Biases in MAIC seem to be unaffected when varying the degree of covariate
overlap.
5.2 Unbiasedness of variance of treatment effect
In MAIC and the Bucher method, the variability ratio of treatment effect estimates is
close to one under all simulation scenarios (Figure 3). This suggests that standard error
estimates for the methods are unbiased.
In STC, variability ratios are well above one in all 162 scenarios. Hence, there is a
consistent overestimation of the variability of the treatment effect estimate. This over-
estimation can be attributed to the “covariate simulation” approach, where adjusted A
vs. C treatment effects are derived by averaging the predicted log hazards for individual
patients. The fitted standard error of each individual linear prediction is the standard
error of its estimated mean value at a given value of the predictors. If this error is av-
eraged over the simulated patients, it represents the expected error in the mean linear
predictor for a random BC patient. However, the treatment effect and its error should be
taken averaging over the whole BC population, characterized by the approximate joint
distribution of its covariates, as opposed to averaging predictions for a randomly chosen
individual.
Variability ratios for the original “plug-in” approach to STC are very close to one
across all scenarios, suggesting that any bias in the estimated variances is negligible.
The covariate simulation artificially inflates the uncertainty of the estimated treatment
effect, without addressing the non-linearity bias of the plug-in approach. The overstated
uncertainty is an important issue, as it will be propagated through the cost-effectiveness
analysis and may lead to inappropriate decision-making [53].
5.3 Randomization validity
Figure 4 shows the empirical coverage rates for the methods across all scenarios. The em-
pirical coverage rate should be approximately equal to the nominal coverage rate, in this
case 0.95 for 95% confidence intervals, to obtain appropriate type I error rates for testing
a “no effect” null hypothesis. Theoretically, the empirical coverage rate is statistically
significantly different to 0.95 if, roughly, it is less than 0.9365 or more than 0.9635, as-
suming 1,000 independent simulations per scenario. These values differ by approximately
two standard errors from the nominal coverage rate.
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Figure 3: Variability ratio across all simulation scenarios. MAIC: matching-adjusted
indirect comparison; STC: simulated treatment comparison.
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In general, empirical coverage rates for MAIC are not significantly different from the
advertised nominal coverage rate; only three scenarios have a rate below 0.9365 and eleven
empirical coverage rates are above 0.9635. Almost all empirical coverage rates appear to
be appropriate under MAIC: generally, these are within simulation error of 95% and never
fall below 90%, i.e., never at least double the nominal rate of error. As mentioned in
subsection 5.1, any bias does not appear to degrade the coverage rates in this method.
On the other hand, overcoverage is a pervasive problem in STC, for which 145 of
162 scenarios have empirical coverage rates above 0.9635. Poor coverage rates are a de-
composition of both the bias and the standard error used to compute the width of the
confidence intervals. In the case of STC, overcoverage is attributed to the additional vari-
ation introduced by covariate simualtion discussed in subsection 5.2. The coverage rates
only fall under the most important determinants of bias, e.g. moderate effect-modifying
interactions and very strong prognostic variable effects. Under these conditions, the bias
of the STC treatment effect is high enough to shift the coverage rates negatively and may
pull these closer to 0.95. However, this is a result of compounding two problems: high
bias and incorrectly constructed interval estimates. In the “plug-in” approach to STC,
variances of the treatment effect are generally unbiased and poor coverage is exclusively
undercoverage, induced by the bias in the treatment effect and not by the construction of
the confidence intervals.
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From a frequentist viewpoint [54], confidence intervals and P -values from the Bucher
method are not confidence valid, i.e., the 95% confidence intervals are not guaranteed to
include the true treatment effect at least 95% of the time, for all scenarios. Coverage
rates deteriorate markedly under the most important determinants of bias. When there
is less overlap between covariate distributions and when interaction effects are stronger,
the induced bias is larger and coverage rates are degraded. Under very strong interactions
with treatment, empirical coverage may drop below 50%. Therefore, the Bucher method
will incorrectly detect significant results a large proportion of times in these scenarios.
Such overconfidence will lead to very high type I error rates for testing a “no effect” null
hypothesis. This is problematic as indirect comparisons are typically used in the context
of decision-making as opposed to prediction.
5.4 Precision and efficiency
Several trends are revealed upon visual inspection of the empirical standard error across
scenarios (Figure 5). As expected, the ESE decreases for all methods (i.e., the estimate
is more precise) as the number of subjects in the AC trial increases. The strengths of
interaction effects and of prognostic variable effects appear to have a negligible impact on
the precision of population adjustment methods.
The degree of covariate imbalance has an important influence on the ESE and popu-
lation adjustment methods incur losses of precision when covariate overlap is poor. This
is expected as regression adjustment methods such as STC require greater extrapolation
when the covariate imbalance is larger [13]. In reweighting methods such as MAIC, ex-
trapolation is not even possible. Some observations in the patient-level data are assigned
extreme weights when covariate overlap is poor. Effective sample sizes are reduced as a
relatively small number of observations dominate the reweighted sample and precision de-
teriorates. In MAIC, the presence of correlation mitigates the effect of increasing covariate
imbalance on a consistent basis. ESE for the Bucher method does not vary across different
degrees of covariate overlap, as these are not considered by the method, and overprecise
estimates are produced.
Figure 6 is inspected in order to explore patterns in the mean square error, with a
particular focus on MAIC. Contrary to ESE, MSE also takes into account the true value
of the estimand as it incorporates the bias. Hence, main drivers of bias and ESE are
generally key properties for MSE. For instance, estimates are less accurate for MAIC
when prognostic variable effects are stronger, AC sample sizes are smaller and covariate
overlap is poorer. As bias is negligible for MAIC, precision is the driver of accuracy. On
the contrary, as the Bucher method is systematically biased and overprecise, the driver of
accuracy is bias. Poor accuracy in STC is driven by both bias and lack of precision, partic-
ularly under low sample sizes and strong prognostic variable effects. STC was consistently
less accurate than MAIC, with larger mean square errors in all simulation scenarios. In
some cases where the STC bias was strong, e.g. very strong prognostic variable effects
and moderate effect-modifying interactions, STC even increased the MSE compared to
the Bucher method. Both implementations of STC produced virtually identical ESEs and
MSEs.
In accordance with the trends observed for the ESE, the MSE is also very sensitive
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to the value of N and decreases for all methods as N increases. We highlight that the
number of subjects in the BC trial (not varied in this simulation study) is a less important
performance driver than the number of subjects in AC; while it contributes to sampling
variability, the reweighting or regressions are performed in the AC patient-level data.
6 Discussion
In this section, we discuss the implications of, and recommendations for, performing pop-
ulation adjustment, based on the simulation study. We focus on MAIC as a population
adjustment method, given the systematic bias and potentially underestimated precision in
STC. Finally, we highlight potential limitations of the simulation study, primarily relating
to the extrapolation of its results to practical guidance.
Before performing population adjustment, it is important to assess the magnitude
of the bias induced by effect modifier imbalances. Such bias depends on the degree of
covariate overlap and on the strength of interaction effects, i.e., the effect modifier status of
the covariates. The combination of these two factors determines the level of bias reduction
that would be achieved with population adjustment.
We know that the accuracy or efficiency of an estimate, as measured by the mean square
error, is a composite of unbiasedness and precision. Inevitably, due to bias-variance trade-
offs, the increase in variability that we are willing to accept with population adjustment
depends on the magnitude of the bias that would be corrected. Such variability is largely
driven by the degree of covariate overlap and by the AC sample size. Hence, while the
potential extent of bias correction increases with greater covariate imbalance, so does the
potential imprecision of the treatment effect estimate.
In our simulation study, this trade-off always favours the bias correction offered by
MAIC over the precision of the Bucher method, implying that the reductions in ESS based
on unstable weights are merited, even under lower covariate imbalance. Across scenarios,
the relative accuracy of MAIC with respect to that of the Bucher method improves under
greater degrees of covariate imbalance. It is worth noting that, even in scenarios where
the Bucher method is relatively accurate, it is still a flawed method in the context of
decision-making due to overprecision and undercoverage.
The magnitude of the bias that would be corrected with population adjustment also
depends on the strength of interaction effects, i.e., the effect modifier status of the co-
variates. In the simulation study, the lowest effect-modifying interaction coefficient was
− log(0.67) = 0.4. Given two effect modifiers, it induced biases in the treatment effect of
relatively low magnitudes: 0.16, 0.24 and 0.32, for strong, moderate and poor covariate
overlap, respectively. Despite this, MAIC was consistently more efficient than the Bucher
method in these scenarios. Larger interaction effects warrant greater bias reduction but do
not degrade the precision of the population-adjusted estimate. Hence, the relative accu-
racy of MAIC with respect to the Bucher method improves further as the effect-modifying
coefficients increase.
In the simulation study, we know that population adjustment is required as we set
the cross-trial imbalances between covariates and have specified some of these as effect
modifiers. Most applications of population adjustment present evidence of the former, e.g.
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through tables of baseline characteristics with covariate means and proportions. However,
quantitative evidence justifying the effect modifier status of the selected covariates is rarely
brought forward. Presenting this type of supporting evidence is of capital importance when
justifying the use of population adjustment.
Typically, the selection of effect modifiers is supported by clinical expert opinion. How-
ever, clinical expert judgment and subject-matter knowledge are fallible when determining
effect modifier status because (1) the therapies being evaluated are often novel, and (2)
effect modifier status is scale-specific; clinical experts may not have the mathematical in-
tuition to assess whether covariates are effect modifiers on the linear predictor scale (as
opposed to the natural outcome scale).
Therefore, applications of population adjustment often balance all available covariates
on the grounds of expert opinion, probably because the clinical experts cannot rule out
interactions with treatment for any of the baseline characteristics. Presenting quantita-
tive evidence along with clinical expert opinion would help establish whether population
adjustment is necessary. As proposed by Phillippo et al. [6], we encourage the analyst to
fit regression models with interaction terms to the IPD for an exploratory assessment of
effect modifier status.
It is worth noting that the conclusions of this simulation study are dependent on the
outcome and model type. We have considered survival outcomes and Cox proportional
hazards models, as these are the most prevalent outcome and modelling framework in
MAIC and STC applications. However, further simulation studies are required with alter-
native outcomes and models. For example, exploratory simulations with binary outcomes
and logistic regression have found that the precision of MAIC is more affected by low
effective sample sizes than seen for survival outcomes.
Furthermore, we highlight that we have only considered and adjusted for two effect
modifiers that induce bias in the same direction. In real applications of population ad-
justment, it is not uncommon to see more than 10 being balanced [23]. As this simulation
study considered percentage reductions in effective sample size for MAIC that are repre-
sentative of scenarios encountered in NICE TAs (see Appendix B of the Supplementary
Material), real applications will have imbalances for each individual covariate that are
smaller than those considered in this study. In addition, the effect-modifying interactions
for each covariate could be in opposite directions and thus, the induced biases could cancel
out.
This simulation study also assumed that there is no model misspecification. For in-
stance, it assumed that 1) complete information on effect modifiers is available from both
trials and that all effect modifiers have been accounted for, and 2) effect modifiers interact
with treatment in the same way in trial AC and trial BC.
In practice, the first assumption may be problematic because it is difficult to ascertain
the effect modifier status of covariates, particularly for new treatments with limited prior
empirical evidence and clinical domain knowledge. Hence, the analyst may select the
effect modifiers incorrectly. In addition, effect modifier status could be determined on the
wrong scale or information on some effect modifiers could be unavailable or unpublished
for one of the trials. The second assumption may also be hard to meet if the competing
interventions do not belong to the same class, and have dissimilar mechanisms of action
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or clinical properties.
Another source of misspecification in population adjustment is the incorrect specifi-
cation of the joint distribution of BC covariates. In MAIC, it is implicitly assumed that
correlations between covariates are identical across trials or that the joint distribution
of the BC baseline characteristics is the product of the published marginal distributions
[13]. In the “covariate simulation” approach to STC, assumptions are more explicit: it
is assumed that (1) the joint distribution of the BC covariates is specified correctly, by
the combination of the specified marginal distributions and correlation structure, and (2)
that the pairwise correlations and the form of the covariates’ marginal distributions are
identical across trials.
More generally, the simulation study uses the correct data-generating mechanism, i.e.,
it is known that there is a linear relationship between the effects and the log hazard ratio,
and that the covariates have Bernoulli-distributed marginals. In real applications, the
data-generating process is not known.
Regression adjustment methods such as STC, which specify an outcome model explic-
itly, are prone to this type of misspecification. However, there is also an implicit outcome
model in MAIC; treatment and effect modifiers are assumed to be additive on the log haz-
ard ratio scale. Hence, all population adjustment methods are susceptible to bias when
effect modifiers have a non-linear effect on the log hazard, e.g. age in cardiovascular dis-
ease. Future simulation studies should assess the robustness of population adjustment to
failures in assumptions under different degrees of data availability and model misspecifi-
cation.
Finally, it is worth noting that, while this article focuses on anchored indirect compar-
isons, most applications of population adjustment in HTA are in the unanchored setting
[23]. We stress that RCTs deliver the gold standard for evidence on effectiveness and that
unanchored comparisons make very strong assumptions which are largely considered im-
possible to meet (absolute effects are conditionally constant as opposed to relative effects
being conditionally constant) [6, 13]. Unanchored comparisons effectively assume that
absolute outcomes can be predicted from the covariates and that all effect modifiers and
prognostic variables are accounted for.
However, the number of unanchored comparisons is likely to continue growing as regu-
lators are, increasingly and particularly in oncology, approving new treatments on the basis
of single-armed evidence or disconnected networks [55, 56]. As pharmaceutical companies
use this type of evidence to an increasing extent to obtain regulatory approval, reimburse-
ment agencies will, in turn, be increasingly asked to evaluate interventions where only
this type of evidence is available. Therefore, further examinations of the performance of
population adjustment methods must be performed in the unanchored setting.
7 Concluding remarks
In the performance measures we considered, MAIC was the least biased, most accurate
and only randomization-valid method. We therefore recommend its use for survival out-
comes. STC was systematically biased and should be avoided in settings with a non-linear
link function. The Bucher method is systematically biased and overprecise when there are
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imbalances in effect modifiers and interaction effects that induce bias in the treatment
effect. Future simulation studies should assess population adjustment methods with dif-
ferent outcome types and under model misspecification.
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